Oncosec tech to deliver genetically engineered proteins directly into tumours

By Flora Southey contact

- Last updated on GMT


Related tags: Dna, Medicine

Avacta says a research collaboration using Oncosec’s gene delivery technology could lead to the development of gene delivered Affimer immunotherapies.

The partnership teams Avacta’s Affimer protein platform – based on a small human protein that can be engineered to bind with high specificity and affinity to a wide range of protein targets – with Oncosec’s ImmunoPulse technology, to deliver DNA encoded proteins directly into animal model tumours.

DNA encoded immune-modulatory Affimers investigated in the collaboration include Avacta’s PD-L1 inhibitor (AVA04).

The collaboration “will show how well the Oncosec Immunopulse and Avacta Affimer technology work together to deliver clinical relevant dosing levels and efficacy of the PD-L1 blockade in an animal model,” ​said Avacta CEO Alistair Smith.

“Both companies will also potentially benefit in the future from the development of an Affimer therapeutic candidate delivered using the Oncosec technology through a licensing model,” ​he told us.

The programme is designed to generate proof of concept data, to create immunotherapy combinations for clinical development and/or licensing.

“If these data are good then there is the potential to partner with larger pharmaceutical companies who are interested in gene delivery of small therapeutic proteins most likely in oncology,” ​said Smith.

The deal marks Avacta’s third collaboration for Affimer gene therapies, with Moderna Therapeutics and FIT Biotech also using the platform.

Earlier this month, Avacta signed a licensing deal​ to develop drug conjugates using with Glythera. 

Related topics: Drug Delivery, Delivery technologies

Related news

Related products

Local lab Data Management

Local lab Data Management

Q2 Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Follow us


View more